Monitor the pace of ATM sales and any use-of-proceeds announcements. The offering may create near-term downward pressure due to dilution, but the strong cash position and positive clinical data provide a floor. Watch for potential acceleration of sales if the stock remains elevated post-earnings.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $28.74entry
- T+1 · 6mo ago −1.74%α −1.41% · $28.24
- T+5 · 6mo ago −2.16%α −3.29% · $28.12
- T+20 · 6mo ago −1.18%α −3.96% · $28.40
- T+60 · 4mo ago +23.52%α +21.46% · $35.50
Price Chart
How similar events traded
Executive Summary
IDEAYA Biosciences filed a prospectus supplement on May 5, 2026, for an at-the-market (ATM) offering of up to $156.6 million in common stock, the remaining portion of a $350 million facility established in January 2024. The filing coincides with the same day's positive earnings release and clinical trial results. The offering is dilutive (~6.3% of market cap) but the company's strong cash position ($973M) and positive pipeline momentum may offset some negative sentiment.
Key Facts
- Up to $156,552,996.81 in common stock remains available under the ATM facility (already sold $193,447,003.19)
- Stock price as of May 1, 2026: $28.19 per share
- Net tangible book value per share as of March 31, 2026: $10.67; dilution of $16.52 per share to new investors
- Company had ~$973 million in cash, cash equivalents, and marketable securities as of March 31, 2026
- Commission to Jefferies: up to 3.0% of gross proceeds
- Positive Phase 2/3 OptimUM-02 trial results announced on April 13, 2026, met primary endpoint
- Proceeds for general corporate purposes, including clinical development and potential commercialization
Financial Impact
Dilution of approximately $16.52 per share on the assumed $28.19 offering price; offering size ~6.3% of market cap
Risk Factors
- Continued dilution from ongoing ATM sales
- Potential overhang from future equity issuances
- Execution risk in commercialization with raised capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-206788 |
| Document: d30692dexfilingfees.htm | 0001193125-26-206788 |
| Document: 0001193125-26-206788-index-headers.html | 0001193125-26-206788 |
| Document: 0001193125-26-206788-index.html | 0001193125-26-206788 |
| Document: 0001193125-26-206788.txt | 0001193125-26-206788 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers